12 Other operating income/expenses

12 Other operating income/expenses

 

 

 

€ million

2019

2018

Provisions

15

−19

Impairment trade receivable

−4

−4

Gain/Loss (−) on disposal of non-current assets

7

−7

Reimbursement by third parties for development expenses

4

1

Grants received

15

15

Collaboration agreement for the development and commercialization of Evenity®

8

−10

Other income/expenses (−)

3

0

Total other operating income/expenses (−)

48

−24

 

 

 

The result of the collaboration agreement with Amgen for the development and commercialization of Evenity® amounted to € 8 million income (compared to € −10 million expenses in 2018). All recharges of development and commercialization expenses to/from Amgen are classified as other operating income/expenses. The equivalent total net recharges as per 31 December 2019 consisted of € 14 million marketing and selling income (€ 2 million in 2018) and € −6 million development expenses (€ −12 million in 2018).

The provisions are mainly related to VAT risks and grant recoverability risks.